Managing allergic rhinitis: The role of pharmacotherapy

Adrienne M. Tiñana, R. Matthew Bloebaum, J. Andrew Grant

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacological therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted on the basis of the response to therapy, with the goal of symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second-generation antihistamines are better options than the first-generation antihistamines because of their superior adverse-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

Original languageEnglish (US)
Pages (from-to)312-318
Number of pages7
JournalDrug Benefit Trends
Volume21
Issue number10
StatePublished - 2009

Fingerprint

Drug Therapy
Histamine Antagonists
Pruritus
Adrenal Cortex Hormones
Non-Sedating Histamine H1 Antagonists
Ipratropium
Sneezing
Cromolyn Sodium
Therapeutics
Nose
Allergens
Allergic Rhinitis
Pharmacology

Keywords

  • Allergic rhinitis
  • Antihistamines
  • Cromolyn
  • Intranasal corticosteroids
  • Ipratropium
  • Leukotriene receptor antagonists

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy

Cite this

Tiñana, A. M., Bloebaum, R. M., & Grant, J. A. (2009). Managing allergic rhinitis: The role of pharmacotherapy. Drug Benefit Trends, 21(10), 312-318.

Managing allergic rhinitis : The role of pharmacotherapy. / Tiñana, Adrienne M.; Bloebaum, R. Matthew; Grant, J. Andrew.

In: Drug Benefit Trends, Vol. 21, No. 10, 2009, p. 312-318.

Research output: Contribution to journalArticle

Tiñana, AM, Bloebaum, RM & Grant, JA 2009, 'Managing allergic rhinitis: The role of pharmacotherapy', Drug Benefit Trends, vol. 21, no. 10, pp. 312-318.
Tiñana AM, Bloebaum RM, Grant JA. Managing allergic rhinitis: The role of pharmacotherapy. Drug Benefit Trends. 2009;21(10):312-318.
Tiñana, Adrienne M. ; Bloebaum, R. Matthew ; Grant, J. Andrew. / Managing allergic rhinitis : The role of pharmacotherapy. In: Drug Benefit Trends. 2009 ; Vol. 21, No. 10. pp. 312-318.
@article{33c27cd6d6b74f5886608fbeedf65248,
title = "Managing allergic rhinitis: The role of pharmacotherapy",
abstract = "While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacological therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted on the basis of the response to therapy, with the goal of symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second-generation antihistamines are better options than the first-generation antihistamines because of their superior adverse-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.",
keywords = "Allergic rhinitis, Antihistamines, Cromolyn, Intranasal corticosteroids, Ipratropium, Leukotriene receptor antagonists",
author = "Ti{\~n}ana, {Adrienne M.} and Bloebaum, {R. Matthew} and Grant, {J. Andrew}",
year = "2009",
language = "English (US)",
volume = "21",
pages = "312--318",
journal = "Drug Benefit Trends",
issn = "1080-5826",
publisher = "Cliggott Publishing Co.",
number = "10",

}

TY - JOUR

T1 - Managing allergic rhinitis

T2 - The role of pharmacotherapy

AU - Tiñana, Adrienne M.

AU - Bloebaum, R. Matthew

AU - Grant, J. Andrew

PY - 2009

Y1 - 2009

N2 - While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacological therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted on the basis of the response to therapy, with the goal of symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second-generation antihistamines are better options than the first-generation antihistamines because of their superior adverse-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

AB - While avoidance measures are a key component of the treatment of allergic rhinitis, pharmacological therapies are often needed to adequately control symptoms. Intranasal corticosteroids are highly effective and are particularly useful in patients with moderate to severe disease. After use for 1 to 2 weeks, the patient should be reevaluated and the dose adjusted on the basis of the response to therapy, with the goal of symptom relief at the lowest effective dose. Antihistamines, which may be given alone or with intranasal corticosteroids, control the patient's sneezing, nasal itching, rhinorrhea, and conjunctival itching. For most patients, the second-generation antihistamines are better options than the first-generation antihistamines because of their superior adverse-effect profiles. When using cromolyn to manage seasonal symptoms, it is advisable to begin therapy 2 weeks before the expected allergen exposure. Ipratropium is helpful in patients whose main symptom is rhinorrhea.

KW - Allergic rhinitis

KW - Antihistamines

KW - Cromolyn

KW - Intranasal corticosteroids

KW - Ipratropium

KW - Leukotriene receptor antagonists

UR - http://www.scopus.com/inward/record.url?scp=71949094837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949094837&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:71949094837

VL - 21

SP - 312

EP - 318

JO - Drug Benefit Trends

JF - Drug Benefit Trends

SN - 1080-5826

IS - 10

ER -